Dependence of Postoperative Scar Condition on a Baseline Level of Matrix Metalloproteinases
DOI: 10.32364/2587-6821-2026-10-6-7
Dependence of Postoperative Scar Condition on a Baseline Level of Matrix Metalloproteinases
V.V. Gladko1, G.A. Flaks1, R.A. Pakhomova1, M.M. Magomedova2, Sh.R. Abdullaev3
1 ROSBIOTECH, Moscow, Russian Federation
2 Olymp Clinic LLC, Moscow, Russian Federation
3 Plastic Surgery and Cosmetology Institute JSC, Moscow, Russian Federation
Background: a vast arsenal of methods and medications that can improve condition of a pathological scar is available for a dermatologist despite an insignificant effect. Surgical treatment is naturally an alternative to conservative one. Advanced technologies implemented into medical practice open up new opportunities in studying the course of a wound process. Thus, matrix metalloproteinases (MMPs) are of interest.
Aim: to determine prognostic value of MMP assay in scar formation in a postoperative period.
Materials and Methods: 51 patients were enrolled. 34 of them had a postoperative or post-traumatic scar (Group 1 — 18 patients with hypertrophic scars, Group 2 — 16 patients with keloid scars), and 17 patients had undergone an elective plastic surgery (abdominoplasty). Serum levels of gelatinases (MMP-2 and MMP-9) were determined at baseline and on Day 3 after the surgery. According to the indications, a pulsating dye laser (PDL) was applied to the scar before the surgery, and IPL therapy was performed after it. Silicone gel and silicone patches were used to prevent a pathological scar. The scar condition was assessed according to the POSAS scale.
Results: the preoperative treatment and subsequent surgery led to a significant decrease in a number of patients with high MMP levels (≥160 µmol/l/h) from 26 (51%) to 17 (33%). The therapy method, as well as a combination of methods, was chosen on a case-by-case basis. The combination was used in all patients who were at risk of an unfavorable outcome. Hypertrophic scars were detected in 3 (6%) patients, and, in particular, in 1 patient (Group 3) whose MMP level exceeded 190 µmol/l/h on Day 3. Keloid recurrence was reported in 2 (4%) patients (Group 2) whose MMP levels exceeded 190 µmol/l/h on Day 3. Keloid recurrence rate was 12.5% of the scar group subjects. Assessment of treatment outcomes was comparable between a patient and a doctor.
Conclusion: to manage patients with pathological scars, an individualized approach involving a combined use of various treatment methods should be followed. MMP blood level may become an important predictor of a pathological scar.
Keywords: hypertrophic scar, keloid scar, matrix metalloproteinases, abdominoptosis, abdominoplasty, hyperpigmentation, hypervascularization, combined treatment, POSAS scale.
For citation: Gladko V.V., Flaks G.A., Pakhomova R.A., Magomedova M.M., Abdullaev Sh.R. Dependence of Postoperative Scar Condition on a Baseline Level of Matrix Metalloproteinases. Russian Medical Inquiry. 2026;10(6):382–387 (in Russ.). DOI: 10.32364/2587-6821-2026-10-6-7
About the authors:
Viktor V. Gladko — Dr. Sc. (Med.), Professor, Head of the Department of Skin and Venereal Diseases with a Cosmetology Course of the Medical Institute of Continuing Education, ROSBIOTECH; 11, Volokolamskoe road, Moscow, 125080, Russian Federation; ORCID iD 0000-0002-2173-4383
Grigoryi A. Flaks — Dr. Sc. (Med.), Professor, Professor of the Department of Skin and Venereal Diseases of the Medical Institute of Continuing Education, ROSBIOTECH; 11, Volokolamskoe road, Moscow, 125080, Russian Federation; ORCID iD 0009-0007-3298-3389
Regina A. Pakhomova — Dr. Sc. (Med.), Associate Professor, Head of the Department of Plastic Surgery of the Medical Institute of Continuing Education, ROSBIOTECH; 11, Volokolamskoe road, Moscow, 125080, Russian Federation; ORCID iD 0000-0002-3681-4685
Madina M. Magomedova — Plastic Surgeon, Olymp Clinic LLC; 7/1, Sadovaya-Sukharevskaya str., Moscow, 129090, Russian Federation; ORCID iD 0000-0003-4326-2548
Shamil R. Abdullaev — Plastic Surgeon, Plastic Surgery and Cosmetology Institute JSC; 27, Olkhovskaya str., Moscow, 105066, Russian Federation; ORCID iD 0009-0001-8832-9622
Contact information: Regina A. Pakhomova, e-mail: PRA5555@mail.ru
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interest.
Received 10.06.2026.
Revised 17.06.2026.
Accepted 30.06.2026.
2. Qi W., Xiao X., Tong J., Guo N. Progress in the clinical treatment of keloids. Front Med. 2023;10:1284109. DOI: 10.3389/fmed.2023.1284109
3. Артыков К.П., Саидов М.С., Мухамадиева К.М. Проблемы хирургического лечения келоидных рубцов кожи. Вестник Авиценны. 2013;3:91–94. DOI: 10.25005/2074-0581-2013-15-3-91-94. Artikov K.P., Saidov M.S., Mukhamadieva K.M. Problems of surgical treatment keloid cicatrices of skin. Avicenna Bulletin. 2013;3:91–94 (in Russ.). DOI: 10.25005/2074-0581-2013-15-3-91-94
4. Ahmad N., Anker A., Klein S. et al. Autologous Fat Grafting — A Panacea for Scar Tissue Therapy? Cells. 2024;13(16):1384. DOI: 10.3390/cells13161384
5. Bassiouni W., Ali M., Schulz R. Multifunctional intracellular matrix metalloproteinases: implications in disease. FEBS J. 2021;288(24):7162–7182. DOI: 10.1111/febs.15701
6. Yu D., Lai P., Yan T. et al. Quantifying the Matrix Metalloproteinase 2 (MMP2) Spatially in Tissues by Probe via MALDI Imaging Mass Spectrometry. Front Chem. 2021;9:786283. DOI: 10.3389/fchem.2021.786283
7. Martins V.L., Caley M., O'Toole E.A. Matrix metalloproteinases and epidermal wound repair. Cell Tissue Res. 2013;351(2):255–268. DOI: 10.1007/s00441-012-1410-z
8. Chuang H.M., Chen Y.S., Harn H.J. The Versatile Role of Matrix Metalloproteinase for the Diverse Results of Fibrosis Treatment. Molecules. 2019;24(22):4188. DOI: 10.3390/molecules24224188
9. Mustafa S., Koran S., AlOmair L. Insights Into the Role of Matrix Metalloproteinases in Cancer and its Various Therapeutic Aspects: A Review. Front Mol Biosci. 2022;9:896099. DOI: 10.3389/fmolb.2022.896099
10. Waller V., Pruschy M. Combined Radiochemotherapy: Metalloproteinases Revisited. Front Oncol. 2021;11:676583. DOI: 10.3389/fonc.2021.676583
11. Trentini A., Manfrinato M.C., Castellazzi M., Bellini T. Sex-Related Differences of Matrix Metalloproteinases (MMPs): New Perspectives for These Biomarkers in Cardiovascular and Neurological Diseases. J Pers Med. 2022;12(8):1196. DOI: 10.3390/jpm12081196
This work is licensed under a Creative Commons «Attribution» 4.0 License.
